Welcome to Paid Research Studies




  • Conditions:   Non-Hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Hematopoietic Cell Transplantation;   Drug: Tbo-filgrastim
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Meloxicam;   Drug: Filgrastim
    Sponsors:   Sherif S. Farag;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Granulocyte Colony-Stimulating Factor;   Chemotherapy-induced Neutropenia;   Chemotherapy-Induced Febrile Neutropenia;   Pediatric Cancer
    Intervention:   Drug: Granulocyte Colony-Stimulating Factor
    Sponsor:   University of Mississippi Medical Center
    Recruiting

  • Conditions:   Malignant Melanoma;   Head and Neck Cancer
    Intervention:   Drug: Filgrastim
    Sponsors:   University of Colorado, Denver;   Karsh Family Research Fund
    Recruiting

  • Condition:   Bone Pain
    Interventions:   Drug: Loratadine;   Drug: Placebo
    Sponsor:   University of Michigan
    Recruiting

  • Conditions:   Hematological Malignancy;   Neutropenia
    Intervention:  
    Sponsor:   Aaron Cumpston, PharmD, BCOP
    Recruiting

  • Condition:   Postmenopausal Symptoms
    Interventions:   Biological: G-CSF;   Other: Placebo/Saline
    Sponsors:   MenoGeniX, Inc.;   National Institutes of Health (NIH);   National Institute on Aging (NIA)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   de Novo Myelodysplastic Syndrome;   High Risk Myelodysplastic Syndrome;   Inv(16);   Myelodysplastic Syndrome With Excess Blasts;   t(16;16);   t(8;21);   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Biological: Filgrastim-sndz;   Drug: Fludarabine Phosphate;   Drug: Gemtuzumab Ozogamicin;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aplastic Anemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Biological: Filgrastim;   Drug: Methylprednisolone;   Biological: Pegfilgrastim
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Lymphoid Leukemia;   Lymphoma;   Leukemia;   Myeloma;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Recurrent Acute Myeloid Leukemia, Adult;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: mycophenolate mofetil;   Biological: Sargramostim;   Biological: Filgrastim
    Sponsors:   Virginia Commonwealth University;   Massey Cancer Center
    Recruiting

  • Condition:   Atherosclerosis, Coronary
    Interventions:   Drug: Autologous CD34+ Cells;   Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Blood Donor;   Leukocyte Transfusion;   Granulocyte Colony-Stimulation Factor;   Blood Component Removal
    Interventions:   Drug: Filgrastim (G-CSF);   Drug: Dexamethasone
    Sponsor:   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Mozobil
    Sponsor:   Siddhartha Ganguly
    Recruiting

  • Conditions:   Brain Tumor;   Brain Tumor, Recurrent;   Brain Tumor, Refractory;   Brain Tumor, Pediatric;   Medulloblastoma;   Medulloblastoma Recurrent;   Medulloblastoma, Non-WNT/Non-SHH;   Medulloblastoma, Non-WNT/Non-SHH, Group 3;   Medulloblastoma, Non-WNT/Non-SHH, Group 4;   Brain Cancer;   CNS Cancer;   CNS Tumor;   CNS Neoplasm
    Interventions:   Drug: Prexasertib;   Drug: Cyclophosphamide;   Drug: Gemcitabine;   Biological: filgrastim;   Biological: peg-filgrastim
    Sponsors:   St. Jude Children's Research Hospital;   Eli Lilly and Company
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Evomela;   Procedure: Autologous Stem Cell Infusion;   Drug: G-CSF;   Drug: Palifermin
    Sponsors:   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
    Not yet recruiting

  • Conditions:   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Biological: Filgrastim;   Biological: Filgrastim-sndz;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate;   Drug: Mitoxantrone;   Drug: Sorafenib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Human Papilloma Virus;   Squamous Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   HPV-Related Squamous Cell Carcinoma;   HNSCC
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Nivolumab;   Radiation: Radiation;   Drug: Hydroxyurea Pill;   Drug: 5-fluorouracil;   Drug: Filgrastim Injection;   Drug: Cisplatin
    Sponsor:   University of Chicago
    Not yet recruiting

  • Conditions:   Neuroendocrine Tumors;   Neoplasms;   Cancer;   Tumors
    Interventions:   Drug: TAS-102;   Drug: Temozolomide;   Drug: Filgrastim;   Drug: Pegfilgrastim
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   Taiho Pharmaceutical Co., Ltd.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Drug: Docetaxel;   Drug: Ribociclib;   Drug: Prednisone;   Drug: Filgrastim
    Sponsors:   Rahul Aggarwal;   Novartis
    Recruiting

  • Conditions:   Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Ganglioglioma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Pleomorphic Xanthoastrocytoma, Anaplastic;   Atypical Teratoid/Rhabdoid Tumor;   Brain Cancer;   Brain Tumor;   Central Nervous System Neoplasms;   Choroid Plexus Carcinoma;   CNS Embryonal Tumor With Rhabdoid Features;   Ganglioneuroblastoma of Central Nervous System;   CNS Tumor;   Embryonal Tumor of CNS;   Ependymoma;   Glioblastoma;   Glioma;   Glioma, Malignant;   Medulloblastoma;   Medulloblastoma; Unspecified Site;   Medulloepithelioma;   Neuroepithelial Tumor;   Neoplasms;   Neoplasms, Neuroepithelial;   Papillary Tumor of the Pineal Region (High-grade Only);   Pediatric Brain Tumor;   Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only);   Pineoblastoma;   Primitive Neuroectodermal Tumor;   Recurrent Medulloblastoma;   Refractory Brain Tumor;   Neuroblastoma. CNS;   Glioblastoma, IDH-mutant;   Glioblastoma, IDH-wildtype;   Medulloblastoma, Group 3;   Medulloblastoma, Group 4;   Glioma, High Grade;   Neuroepithelial Tumor, High Grade;   Medulloblastoma, SHH-activated and TP53 Mutant;   Medulloblastoma, SHH-activated and TP53 Wildtype;   Medulloblastoma, Chromosome 9q Loss;   Medulloblastoma, Non-WNT Non-SHH, NOS;   Medulloblastoma, Non-WNT/Non-SHH;   Medulloblastoma, PTCH1 Mutation;   Medulloblastoma, WNT-activated;   Ependymoma, Recurrent;   Glioma, Recurrent High Grade;   Glioma, Recurrent Malignant;   Embryonal Tumor, NOS;   Glioma, Diffuse Midline, H3K27M-mutant;   Embryonal Tumor With Multilayered Rosettes (ETMR);   Ependymoma, NOS, WHO Grade III;   Ependymoma, NOS, WHO Grade II;   Medulloblastoma, G3/G4;   Ependymoma, RELA Fusion Positive
    Interventions:   Drug: Gemcitabine;   Drug: ribociclib;   Drug: sonidegib;   Drug: trametinib;   Biological: filgrastim
    Sponsors:   St. Jude Children's Research Hospital;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Diffuse Large B Cell Lymphoma;   DLBCL;   Cancer
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Biological: Pegfilgrastim
    Sponsors:   University of Wisconsin, Madison;   Medical College of Wisconsin
    Not yet recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Granulocyte Colony-Stimulating Factor
    Sponsors:   Hackensack Meridian Health;   Amgen
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
    Intervention:   Biological: G-CSF mobilized CD34+ selected cells for transplantation
    Sponsor:   Emory University
    Available

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride;   Drug: Cyclophosphamide;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
    Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Retinoblastoma
    Interventions:   Drug: vincristine;   Drug: topotecan;   Drug: filgrastim;   Drug: PEG-filgrastim;   Drug: carboplatin;   Other: focal therapy;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: MESNA;   Drug: doxorubicin;   Procedure: enucleation;   Radiation: external beam radiation or proton beam radiation
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aplastic Anemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Mycophenolate Mofetil;   Drug: Sorafenib;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Healthy
    Intervention:   Drug: Filgrastim
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Melphalan;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Autologous Stem Cell Infusion;   Biological: Granulocyte colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoma, AIDS-related;   Lymphoma, Large B-Cell, Diffuse
    Interventions:   Biological: Rituximab;   Biological: filgrastim;   Drug: EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diabetes Mellitus, Type 1;   Hypoglycemia;   Autoimmune Diseases;   Diabetes Mellitus
    Interventions:   Drug: Anti-Thymocyte Globulin (ATG);   Drug: Placebo;   Drug: Pegylated GCSF;   Drug: Interleukin 2;   Drug: Etanercept;   Drug: Exenatide
    Sponsors:   Camillo Ricordi and Jay Skyler;   Diabetes Research Institute Foundation
    Not yet recruiting

  • Conditions:   Graft vs Host Disease;   Graft vs Leukemia;   Donor Apheresis
    Intervention:  
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   New York University and New York Genome Center
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: bendamustine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Bleomycin;   Drug: Vincristine;   Drug: Vinblastine;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: DTIC;   Other: Quality of Life Measurements;   Radiation: Radiotherapy
    Sponsors:   St. Jude Children's Research Hospital;   Teva Pharmaceuticals USA;   Seattle Genetics, Inc.
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Acute Myeloid Leukemia;   Myeloid Neoplasm
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Biological: Granulocyte Colony-Stimulating Factor;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
    Interventions:   Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
    Sponsors:   Emory University;   Children's Healthcare of Atlanta
    Recruiting

  • Conditions:   Ewing's Family Tumors;   Renal Tumors;   Hepatoblastoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Primary Malignant Brain Neoplasms;   Retinoblastoma;   Medulloblastoma;   Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET);   Atypical Teratoid/Rhabdoid Tumor (AT/RT);   CNS Tumors;   Germ Cell Tumors
    Interventions:   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Biological: G-CSF;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Leukapheresis;   Drug: Anti-seizure prophylaxis;   Drug: Ursodiol
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Relapsing Multiple Sclerosis;   Relapsing Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Best Available Therapy (BAT)
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   High-Grade Myeloid Neoplasm;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Blasts 10 Percent or More of Peripheral Blood White Cells
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Gemtuzumab Ozogamicin;   Biological: Granulocyte Colony-Stimulating Factor;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Bortezomib
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   B Acute Lymphoblastic Leukemia;   CD22 Positive;   Lymphocytic Neoplasm;   Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Bendamustine;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Biological: Inotuzumab Ozogamicin;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Inherited Immune Deficiencies
    Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Rituximab;   Drug: Blinatumomab
    Sponsors:   M.D. Anderson Cancer Center;   Amgen
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
    Recruiting

  • Conditions:   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Idarubicin;   Drug: Idarubicin Hydrochloride;   Biological: Pegfilgrastim;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neuromyelitis Optica;   Devic's Disease;   NMO Spectrum Disorder
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia With BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Drug: Ponatinib;   Biological: Rituximab;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   Locally Advanced Malignant Neoplasm;   NY-ESO-1 Positive;   Unresectable Malignant Neoplasm
    Interventions:   Other: 18F-FHBG;   Biological: Aldesleukin;   Drug: Busulfan;   Biological: Cellular Therapy;   Procedure: Computed Tomography;   Biological: Filgrastim;   Drug: Fludarabine;   Procedure: Leukapheresis;   Drug: Plerixafor;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   California Institute for Regenerative Medicine (CIRM);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Systemic Sclerosis;   Diffuse Sclerosis Systemic;   Interstitial Lung Disease;   Pulmonary Hypertension
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Thiotepa;   Drug: GM-CSF;   Drug: Intravenous immunoglobulin;   Radiation: Total Body Irradiation
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Lymphoproliferative Disorder;   HHV-8;   Malignancy;   HIV
    Interventions:   Drug: Etoposide;   Drug: Interferon-alpha;   Drug: Rituximab;   Drug: Zidovudine;   Drug: Liposomal Doxorubicin;   Drug: Bortezomib;   Drug: Valganciclovir;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Filgrastim (G-CSF);   Drug: Prednisone;   Drug: Sirolimus;   Other: Observation Only
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Indolent Adult Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegalovirus Positive;   Donor;   Hematopoietic Cell Transplant Recipient;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Myelofibrosis;   Hematopoietic and Lymphoid Cell Neoplasm
    Intervention:   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Procedure: Bone marrow transplantation;   Drug: Cytoxan;   Drug: testosterone cypionate
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD
    Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Breast Cancer;   Triple Negative Breast Cancer
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Pegfilgrastim;   Drug: Filgrastim
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Fanconi Anemia;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Anti-Thymocyte Globulin (Rabbit);   Device: The CliniMACS device;   Drug: G-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Pediatric Brain Tumor Consortium
    Recruiting

  • Condition:   Acute Myelogenous Leukemia
    Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Filgrastim (G-CSF);   Drug: Fludarabine;   Drug: Cytarabine
    Sponsor:   Therapeutic Advances in Childhood Leukemia Consortium
    Recruiting

  • Condition:   Systemic Scleroderma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Triple-negative Breast Cancer
    Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Placebo;   Drug: Nab-paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Filgrastim;   Drug: Pegfilgrastim
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Bladder Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   AIDS-Related Lymphoma;   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   CD20 Negative;   CD20 Positive;   Human Immunodeficiency Virus Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: vinblastine;   Drug: dacarbazine;   Drug: G-CSF
    Sponsor:   Seattle Genetics, Inc.
    Recruiting

  • Conditions:   Childhood Germ Cell Tumor;   Ovarian Cancer;   Teratoma
    Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide;   Drug: paclitaxel;   Drug: thiotepa;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: Mesna;   Biological: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Rhabdomyosarcoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling;   Drug: Irinotecan;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Drug: Doxorubicin;   Drug: Dexrazoxane;   Drug: ^1^1C-methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Burkitt Leukemia;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Burkitt Leukemia;   Recurrent Burkitt Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Acute Lymphoblastic Leukemia;   Refractory Burkitt Leukemia;   Refractory Burkitt Lymphoma;   Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Lymphoblastic Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Etoposide;   Biological: Ofatumumab;   Biological: Pegfilgrastim;   Biological: Rituximab;   Drug: Vincristine Sulfate Liposome
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B Cell Lymphomas
    Interventions:   Drug: Nivolumab;   Biological: Microtransplantation
    Sponsor:   Ahmed Galal, MD
    Recruiting

  • Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Etoposide;   Drug: BCNU;   Drug: AraC;   Drug: Melphalan;   Procedure: Peripheral blood stem cell transplantation;   Biological: G-CSF;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsors:   Washington University School of Medicine;   National Institutes of Health (NIH);   The V Foundation for Cancer Research;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Crohn's Disease
    Interventions:   Biological: autologous CD34-selected peripheral blood stem cells transplant;   Drug: Alemtuzumab;   Drug: ATG;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: G-CSF;   Drug: Mesna
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS);   NK-Cell Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Juvenile Myelomonocytic Leukemia (JMML);   Chronic Myeloid Leukemia (CML)
    Interventions:   Drug: Cyclophosphamide;   Biological: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Biological: G-csf;   Drug: Mesna;   Device: CliniMACS;   Biological: ATG (rabbit);   Drug: Blinatumomab;   Biological: TCRα/β+;   Biological: CD19+;   Biological: CD45RA-depleted DLI
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   Rafic Farah, MD
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting

  • Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Drug: Dose-dense Doxorubicin or dose-dense Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   Hoffmann-La Roche;   Breast International Group;   Alliance Foundation Trials (AFT);   Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU);   Frontier Science and Technology Research Foundation Inc (FS)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Busulfan IV;   Drug: Melphalan IV
    Sponsors:   Loyola University;   Amgen
    Recruiting

  • Condition:   Diffuse Intrinsic Pontine Glioma (DIPG)
    Interventions:   Biological: TTRNA-DC vaccines with GM-CSF;   Biological: TTRNA-xALT;   Drug: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning;   Drug: Dose-Intensified TMZ;   Drug: Td vaccine;   Biological: Autologous Hematopoietic Stem Cells (HSC)
    Sponsors:   University of Florida;   Accelerate Brain Cancer Cure;   Lyla Nsouli Foundation
    Recruiting

  • Condition:   Alcoholic Hepatitis
    Interventions:   Drug: Anakinra and Zinc;   Drug: Granulocyte-colony factor;   Drug: Prednisone;   Drug: Placebos
    Sponsors:   Indiana University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Not yet recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL);   Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
    Interventions:   Drug: Ibrutinib;   Drug: HD- Methotrexate (MTX);   Drug: Rituximab + HD- Methotrexate (MTX)
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Pharmacyclics LLC.;   Janssen Biotech, Inc.
    Recruiting

  • Condition:   DOCK8 Deficiency
    Interventions:   Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex);   Procedure: Donor peripheral blood stem cell mobiliation and collection;   Procedure: Bone Marrow Harvest Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Medulloblastoma;   Central Nervous System Embryonal Tumors
    Interventions:   Drug: Induction;   Drug: Single Cycle Intensive Chemotherapy;   Drug: Tandem 3 Cycle Intensive Chemotherapy
    Sponsors:   Nationwide Children's Hospital;   Children's Hospital Los Angeles
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Conditions:   Germ Cell Tumor;   Teratoma;   Choriocarcinoma;   Germinoma;   Mixed Germ Cell Tumor;   Yolk Sac Tumor;   Childhood Teratoma;   Malignant Germ Cell Neoplasm;   Extragonadal Seminoma;   Non-seminomatous Germ Cell Tumor;   Seminoma
    Interventions:   Drug: paclitaxel;   Drug: ifosfamide;   Drug: cisplatin;   Drug: pegylated G-CSF;   Drug: G-CSF;   Drug: carboplatin;   Drug: etoposide phosphate;   Procedure: stem cell reinfusion
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment of Cancer - EORTC;   Movember Foundation;   Institute of Cancer Research (ICR), United Kingdom;   Cancer Research UK;   UNICANCER;   Irish Group CTI
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Combination Product: ITMHA;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Erwinia asparaginase;   Drug: Sorafenib;   Drug: G-CSF;   Drug: Dexrazoxane;   Biological: Stem Cell Transplant
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting